1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. WHO SHOULD READ THIS REPORT
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1 SECONDARY RESEARCH
1.4.2 DATA ANALYSIS FRAMEWORK
1.4.3 MARKET SIZE ESTIMATION
1.4.4 FORECASTING
1.4.5 PRIMARY RESEARCH AND DATA VALIDATION
2. CANCER/TUMOR PROFILING MARKET – EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT, 2022 - 2030, MILLION USD
3. MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. MARKET DYNAMICS
3.2.1 DRIVERS
3.2.1.1 INCREASING PREVALENCE OF CANCER WORLDWIDE ANTICIPATED TO PROPEL THE MARKET GROWTH
3.2.1.2 RISE IN RESEARCH AND DEVELOPMENT ACTIVITIES AND INCREASING NEW PRODUCT APPROVALS TO BOOST THE MARKET GROWTH
3.2.2 RESTRAINTS
3.2.2.1 HIGH COST OF CANCER PROFILING TESTS TO HAMPER GROWTH OF THE TUMOR PROFILING MARKET
3.2.2.2 POOR REIMBURSEMENT POLICIES AND LACK OF ACCESS TO HEALTHCARE INFRASTRUCTURE REQUIRED FOR CANCER PROFILING ARE LIKELY TO SUPPRESS THE MARKET GROWTH
3.2.3 OPPORTUNITIES
3.2.3.1 HUGE UNMET NEED AND ECONOMIC DEVELOPMENT OF THE DEVELOPING COUNTRIES IN ASIA PACIFIC AND MEA REGION LEVERAGES SIGNIFICANT GROWTH OPPORTUNITIES
4. COVID-19 ANALYSIS
4.1. IMPACT OF COVID-19 ON CANCER OR TUMOR PROFILING MARKET
5. MARKET SHARE ANALYSIS
5.1. MARKET SHARE ANALYSIS OF TOP GLOBAL CANCER/TUMOR PROFILING PROVIDERS, 2022
5.2. MARKET SHARE ANALYSIS OF TOP NORTH AMERICA CANCER/TUMOR PROFILING PROVIDERS, 2022
5.3. MARKET SHARE ANALYSIS OF TOP EUROPE CANCER/TUMOR PROFILING PROVIDERS, 2022
5.4. MARKET SHARE ANALYSIS OF TOP APAC CANCER/TUMOR PROFILING PROVIDERS, 2022
5.5. MARKET SHARE ANALYSIS OF TOP ROW CANCER/TUMOR PROFILING PROVIDERS, 2022
6. PREMIUM INSIGHTS
6.1. PREVALENCE OF CANCER BY KEY COUNTRIES
6.2. OVERVIEW OF CGP TECHNOLOGY VS HOTSPOT TECHNOLOGY
6.3. COMPREHENSIVE GENOME PROFILING:
6.4. CANCER HOT SPOT TESTING
6.5. UPTAKE OF CGP VS HOTSPOT TECHNIQUE IN AMEA REGION
6.6. EXISTING AND EMERGING TECHNOLOGIES OF CANCER/TUMOR PROFILING
6.7. GENOTYPING
6.8. NEXT GENERATION SEQUENCING
6.9. EMERGING TECHNOLOGIES FOR CANCER PROFILING
7. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
7.1. OVERVIEW
7.2. GENOMIC
7.2.1 GENOMIC MARKET, BY REGION
7.2.1.1 NORTH AMERICA GENOMIC MARKET, BY COUNTRY
7.2.1.2 EUROPE GENOMIC MARKET, BY COUNTRY
7.2.1.3 ASIA-PACIFIC GENOMIC MARKET, BY COUNTRY
7.2.1.4 LATIN AMERICA GENOMIC MARKET, BY COUNTRY
7.2.1.5 MIDDLE EAST GENOMIC MARKET, BY COUNTRY
7.2.1.6 AFRICA GENOMIC MARKET, BY COUNTRY
7.3. PROTEOMIC
7.3.1 PROTEOMIC MARKET, BY REGION
7.3.1.1 NORTH AMERICA PROTEOMIC MARKET, BY COUNTRY
7.3.1.2 EUROPE PROTEOMIC MARKET, BY COUNTRY
7.3.1.3 ASIA-PACIFIC PROTEOMIC MARKET, BY COUNTRY
7.3.1.4 LATIN AMERICA PROTEOMIC MARKET, BY COUNTRY
7.3.1.5 MIDDLE EAST PROTEOMIC MARKET, BY COUNTRY
7.3.1.6 AFRICA PROTEOMIC MARKET, BY COUNTRY
7.4. METABOLOMICS
7.4.1 METABOLOMICS MARKET, BY REGION
7.4.1.1 NORTH AMERICA METABOLOMICS MARKET, BY COUNTRY
7.4.1.2 EUROPE METABOLOMICS MARKET, BY COUNTRY
7.4.1.3 ASIA-PACIFIC METABOLOMICS MARKET, BY COUNTRY
7.4.1.4 LATIN AMERICA METABOLOMICS MARKET, BY COUNTRY
7.4.1.5 MIDDLE EAST METABOLOMICS MARKET, BY COUNTRY
7.4.1.6 AFRICA METABOLOMICS MARKET, BY COUNTRY
7.5. EPIGENETICS
7.5.1 EPIGENETICS MARKET, BY REGION
7.5.1.1 NORTH AMERICA EPIGENETICS MARKET, BY COUNTRY
7.5.1.2 EUROPE EPIGENETICS MARKET, BY COUNTRY
7.5.1.3 ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY
7.5.1.4 LATIN AMERICA EPIGENETICS MARKET, BY COUNTRY
7.5.1.5 MIDDLE EAST EPIGENETICS MARKET, BY COUNTRY
7.5.1.6 AFRICA EPIGENETICS MARKET, BY COUNTRY
8. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
8.1. OVERVIEW
8.2. IMMUNOASSAY
8.2.1 IMMUNOASSAY MARKET, BY REGION
8.2.1.1 NORTH AMERICA IMMUNOASSAY MARKET, BY COUNTRY
8.2.1.2 EUROPE IMMUNOASSAY MARKET, BY COUNTRY
8.2.1.3 ASIA-PACIFIC IMMUNOASSAY MARKET, BY COUNTRY
8.2.1.4 LATIN AMERICA IMMUNOASSAY MARKET, BY COUNTRY
8.2.1.5 MIDDLE EAST IMMUNOASSAY MARKET, BY COUNTRY
8.2.1.6 AFRICA IMMUNOASSAY MARKET, BY COUNTRY
8.3. NGS
8.3.1 NGS MARKET, BY REGION
8.3.1.1 NORTH AMERICA NGS MARKET, BY COUNTRY
8.3.1.2 EUROPE NGS MARKET, BY COUNTRY
8.3.1.3 ASIA-PACIFIC NGS MARKET, BY COUNTRY
8.3.1.4 LATIN AMERICA NGS MARKET, BY COUNTRY
8.3.1.5 MIDDLE EAST NGS MARKET, BY COUNTRY
8.3.1.6 AFRICA NGS MARKET, BY COUNTRY
8.4. INSITU HYBRIDIZATION
8.4.1 GLOBAL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
8.4.1.1 FISH MARKET, BY REGION
8.4.1.1.1 NORTH AMERICA FISH MARKET, BY COUNTRY
8.4.1.1.2 EUROPE FISH MARKET, BY COUNTRY
8.4.1.1.3 ASIA-PACIFIC FISH MARKET, BY COUNTRY
8.4.1.1.4 LATIN AMERICA FISH MARKET, BY COUNTRY
8.4.1.1.5 MIDDLE EAST FISH MARKET, BY COUNTRY
8.4.1.1.6 AFRICA FISH MARKET, BY COUNTRY
8.4.1.2 CISH MARKET, BY REGION
8.4.1.2.1 NORTH AMERICA CISH MARKET, BY COUNTRY
8.4.1.2.2 EUROPE CISH MARKET, BY COUNTRY
8.4.1.2.3 ASIA-PACIFIC CISH MARKET, BY COUNTRY
8.4.1.2.4 LATIN AMERICA CISH MARKET, BY COUNTRY
8.4.1.2.5 MIDDLE EAST CISH MARKET, BY COUNTRY
8.4.1.2.6 AFRICA CISH MARKET, BY COUNTRY
8.4.2 INSITU HYBRIDIZATION MARKET, BY REGION
8.4.2.1 NORTH AMERICA INSITU HYBRIDIZATION MARKET, BY COUNTRY
8.4.2.2 EUROPE INSITU HYBRIDIZATION MARKET, BY COUNTRY
8.4.2.3 ASIA-PACIFIC INSITU HYBRIDIZATION MARKET, BY COUNTRY
8.4.2.4 LATIN AMERICA INSITU HYBRIDIZATION MARKET, BY COUNTRY
8.4.2.5 MIDDLE EAST INSITU HYBRIDIZATION MARKET, BY COUNTRY
8.4.2.6 AFRICA INSITU HYBRIDIZATION MARKET, BY COUNTRY
8.5. MASS SPECTROMETRY
8.5.1 MASS SPECTROMETRY MARKET, BY REGION
8.5.1.1 NORTH AMERICA MASS SPECTROMETRY MARKET, BY COUNTRY
8.5.1.2 EUROPE MASS SPECTROMETRY MARKET, BY COUNTRY
8.5.1.3 ASIA-PACIFIC MASS SPECTROMETRY MARKET, BY COUNTRY
8.5.1.4 LATIN AMERICA MASS SPECTROMETRY MARKET, BY COUNTRY
8.5.1.5 MIDDLE EAST MASS SPECTROMETRY MARKET, BY COUNTRY
8.5.1.6 AFRICA MASS SPECTROMETRY MARKET, BY COUNTRY
8.6. PCR
8.6.1 PCR MARKET, BY REGION
8.6.1.1 NORTH AMERICA PCR MARKET, BY COUNTRY
8.6.1.2 EUROPE PCR MARKET, BY COUNTRY
8.6.1.3 ASIA-PACIFIC PCR MARKET, BY COUNTRY
8.6.1.4 LATIN AMERICA PCR MARKET, BY COUNTRY
8.6.1.5 MIDDLE EAST PCR MARKET, BY COUNTRY
8.6.1.6 AFRICA PCR MARKET, BY COUNTRY
8.7. MICROARRAY
8.7.1 MICROARRAY MARKET, BY REGION
8.7.1.1 NORTH AMERICA MICROARRAY MARKET, BY COUNTRY
8.7.1.2 EUROPE MICROARRAY MARKET, BY COUNTRY
8.7.1.3 ASIA-PACIFIC MICROARRAY MARKET, BY COUNTRY
8.7.1.4 LATIN AMERICA MICROARRAY MARKET, BY COUNTRY
8.7.1.5 MIDDLE EAST MICROARRAY MARKET, BY COUNTRY
8.7.1.6 AFRICA MICROARRAY MARKET, BY COUNTRY
8.8. OTHERS
8.8.1 OTHERS MARKET, BY REGION
8.8.1.1 NORTH AMERICA OTHERS MARKET, BY COUNTRY
8.8.1.2 EUROPE OTHERS MARKET, BY COUNTRY
8.8.1.3 ASIA-PACIFIC OTHERS MARKET, BY COUNTRY
8.8.1.4 LATIN AMERICA OTHERS MARKET, BY COUNTRY
8.8.1.5 MIDDLE EAST OTHERS MARKET, BY COUNTRY
8.8.1.6 AFRICA OTHERS MARKET, BY COUNTRY
9. GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION
9.1. OVERVIEW
9.2. RESEARCH APPLICATION
9.2.1 GLOBAL RESEARCH APPLICATION MARKET, BY APPLICATION
9.2.1.1 BIOMARKER DISCOVERY MARKET, BY REGION
9.2.1.1.1 NORTH AMERICA BIOMARKER DISCOVERY MARKET, BY COUNTRY
9.2.1.1.2 EUROPE BIOMARKER DISCOVERY MARKET, BY COUNTRY
9.2.1.1.3 ASIA-PACIFIC BIOMARKER DISCOVERY MARKET, BY COUNTRY
9.2.1.1.4 LATIN AMERICA BIOMARKER DISCOVERY MARKET, BY COUNTRY
9.2.1.1.5 MIDDLE EAST BIOMARKER DISCOVERY MARKET, BY COUNTRY
9.2.1.1.6 AFRICA BIOMARKER DISCOVERY MARKET, BY COUNTRY
9.2.1.2 PERSONALIZED CANCER MEDICINE MARKET, BY REGION
9.2.1.2.1 NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY
9.2.1.2.2 EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY
9.2.1.2.3 ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY
9.2.1.2.4 LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY
9.2.1.2.5 MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY
9.2.1.2.6 AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY
9.2.2 RESEARCH APPLICATION MARKET, BY REGION
9.2.2.1 NORTH AMERICA RESEARCH APPLICATION MARKET, BY COUNTRY
9.2.2.2 EUROPE RESEARCH APPLICATION MARKET, BY COUNTRY
9.2.2.3 ASIA-PACIFIC RESEARCH APPLICATION MARKET, BY COUNTRY
9.2.2.4 LATIN AMERICA RESEARCH APPLICATION MARKET, BY COUNTRY
9.2.2.5 MIDDLE EAST RESEARCH APPLICATION MARKET, BY COUNTRY
9.2.2.6 AFRICA RESEARCH APPLICATION MARKET, BY COUNTRY
9.3. CLINICAL APPLICATION
9.3.1 GLOBAL CLINICAL APPLICATION MARKET, BY APPLICATION
9.3.1.1 ONCOLOGICAL DIAGNOSTICS MARKET, BY REGION
9.3.1.1.1 NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY
9.3.1.1.2 EUROPE ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY
9.3.1.1.3 ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY
9.3.1.1.4 LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY
9.3.1.1.5 MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY
9.3.1.1.6 AFRICA ONCOLOGICAL DIAGNOSTICS MARKET, BY COUNTRY
9.3.1.2 PROGNOSTICS MARKET, BY REGION
9.3.1.2.1 NORTH AMERICA PROGNOSTICS MARKET, BY COUNTRY
9.3.1.2.2 EUROPE PROGNOSTICS MARKET, BY COUNTRY
9.3.1.2.3 ASIA-PACIFIC PROGNOSTICS MARKET, BY COUNTRY
9.3.1.2.4 LATIN AMERICA PROGNOSTICS MARKET, BY COUNTRY
9.3.1.2.5 MIDDLE EAST PROGNOSTICS MARKET, BY COUNTRY
9.3.1.2.6 AFRICA PROGNOSTICS MARKET, BY COUNTRY
9.3.1.3 MONITORING AND TREATMENT MARKET, BY REGION
9.3.1.3.1 NORTH AMERICA MONITORING AND TREATMENT MARKET, BY COUNTRY
9.3.1.3.2 EUROPE MONITORING AND TREATMENT MARKET, BY COUNTRY
9.3.1.3.3 ASIA-PACIFIC MONITORING AND TREATMENT MARKET, BY COUNTRY
9.3.1.3.4 LATIN AMERICA MONITORING AND TREATMENT MARKET, BY COUNTRY
9.3.1.3.5 MIDDLE EAST MONITORING AND TREATMENT MARKET, BY COUNTRY
9.3.1.3.6 AFRICA MONITORING AND TREATMENT MARKET, BY COUNTRY
9.3.1.4 SCREENING MARKET, BY REGION
9.3.1.4.1 NORTH AMERICA SCREENING MARKET, BY COUNTRY
9.3.1.4.2 EUROPE SCREENING MARKET, BY COUNTRY
9.3.1.4.3 ASIA-PACIFIC SCREENING MARKET, BY COUNTRY
9.3.1.4.4 LATIN AMERICA SCREENING MARKET, BY COUNTRY
9.3.1.4.5 MIDDLE EAST SCREENING MARKET, BY COUNTRY
9.3.1.4.6 AFRICA SCREENING MARKET, BY COUNTRY
9.3.2 CLINICAL APPLICATION MARKET, BY REGION
9.3.2.1 NORTH AMERICA CLINICAL APPLICATION MARKET, BY COUNTRY
9.3.2.2 EUROPE CLINICAL APPLICATION MARKET, BY COUNTRY
9.3.2.3 ASIA-PACIFIC CLINICAL APPLICATION MARKET, BY COUNTRY
9.3.2.4 LATIN AMERICA CLINICAL APPLICATION MARKET, BY COUNTRY
9.3.2.5 MIDDLE EAST CLINICAL APPLICATION MARKET, BY COUNTRY
9.3.2.6 AFRICA CLINICAL APPLICATION MARKET, BY COUNTRY
10. GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION
10.1. OVERVIEW
10.2. NORTH AMERICA
10.2.1 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.2.2 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.2.2.1 NORTH AMERICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.2.3 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.2.3.1 NORTH AMERICA RESEARCH APPLICATION MARKET, BY APPLICATION
10.2.3.2 NORTH AMERICA CLINICAL APPLICATION MARKET, BY APPLICATION
10.2.4 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY
10.2.4.1 U.S.
10.2.4.1.1 U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.2.4.1.2 U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.2.4.1.2.1. U.S. INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.2.4.1.3 U.S. CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.2.4.1.3.1. U.S. RESEARCH APPLICATION MARKET, BY APPLICATION
10.2.4.1.3.2. U.S. CLINICAL APPLICATION MARKET, BY APPLICATION
10.2.4.2 CANADA
10.2.4.2.1 CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.2.4.2.2 CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.2.4.2.2.1. CANADA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.2.4.2.3 CANADA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.2.4.2.3.1. CANADA RESEARCH APPLICATION MARKET, BY APPLICATION
10.2.4.2.3.2. CANADA CLINICAL APPLICATION MARKET, BY APPLICATION
10.3. EUROPE
10.3.1 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.2 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.2.1 EUROPE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.3 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.3.1 EUROPE RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.3.2 EUROPE CLINICAL APPLICATION MARKET, BY APPLICATION
10.3.4 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY
10.3.4.1 GERMANY
10.3.4.1.1 GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.4.1.2 GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.4.1.2.1. GERMANY INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.4.1.3 GERMANY CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.4.1.3.1. GERMANY RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.4.1.3.2. GERMANY CLINICAL APPLICATION MARKET, BY APPLICATION
10.3.4.2 FRANCE
10.3.4.2.1 FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.4.2.2 FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.4.2.2.1. FRANCE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.4.2.3 FRANCE CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.4.2.3.1. FRANCE RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.4.2.3.2. FRANCE CLINICAL APPLICATION MARKET, BY APPLICATION
10.3.4.3 UK
10.3.4.3.1 UK CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.4.3.2 UK CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.4.3.2.1. UK INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.4.3.3 UK CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.4.3.3.1. UK RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.4.3.3.2. UK CLINICAL APPLICATION MARKET, BY APPLICATION
10.3.4.4 SPAIN
10.3.4.4.1 SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.4.4.2 SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.4.4.2.1. SPAIN INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.4.4.3 SPAIN CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.4.4.3.1. SPAIN RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.4.4.3.2. SPAIN CLINICAL APPLICATION MARKET, BY APPLICATION
10.3.4.5 ITALY
10.3.4.5.1 ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.4.5.2 ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.4.5.2.1. ITALY INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.4.5.3 ITALY CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.4.5.3.1. ITALY RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.4.5.3.2. ITALY CLINICAL APPLICATION MARKET, BY APPLICATION
10.3.4.6 REST OF THE EUROPE
10.3.4.6.1 REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.3.4.6.2 REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.3.4.6.2.1. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.3.4.6.3 REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.3.4.6.3.1. REST OF THE EUROPE RESEARCH APPLICATION MARKET, BY APPLICATION
10.3.4.6.3.2. REST OF THE EUROPE CLINICAL APPLICATION MARKET, BY APPLICATION
10.4. ASIA-PACIFIC
10.4.1 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.2 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.2.1 ASIA-PACIFIC INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.3 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.3.1 ASIA-PACIFIC RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.3.2 ASIA-PACIFIC CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY
10.4.4.1 CHINA
10.4.4.1.1 CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.1.2 CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.1.2.1. CHINA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.1.3 CHINA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.1.3.1. CHINA RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.1.3.2. CHINA CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.2 INDIA
10.4.4.2.1 INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.2.2 INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.2.2.1. INDIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.2.3 INDIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.2.3.1. INDIA RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.2.3.2. INDIA CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.3 JAPAN
10.4.4.3.1 JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.3.2 JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.3.2.1. JAPAN INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.3.3 JAPAN CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.3.3.1. JAPAN RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.3.3.2. JAPAN CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.4 SOUTH KOREA
10.4.4.4.1 SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.4.2 SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.4.2.1. SOUTH KOREA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.4.3 SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.4.3.1. SOUTH KOREA RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.4.3.2. SOUTH KOREA CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.5 SINGAPORE
10.4.4.5.1 SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.5.2 SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.5.2.1. SINGAPORE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.5.3 SINGAPORE CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.5.3.1. SINGAPORE RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.5.3.2. SINGAPORE CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.6 AUSTRALIA
10.4.4.6.1 AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.6.2 AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.6.2.1. AUSTRALIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.6.3 AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.6.3.1. AUSTRALIA RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.6.3.2. AUSTRALIA CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.7 INDONESIA
10.4.4.7.1 INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.7.2 INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.7.2.1. INDONESIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.7.3 INDONESIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.7.3.1. INDONESIA RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.7.3.2. INDONESIA CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.8 VIETNAM
10.4.4.8.1 VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.8.2 VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.8.2.1. VIETNAM INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.8.3 VIETNAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.8.3.1. VIETNAM RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.8.3.2. VIETNAM CLINICAL APPLICATION MARKET, BY APPLICATION
10.4.4.9 RES OF THE ASIA PACIFIC
10.4.4.9.1 RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.4.4.9.2 RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.4.4.9.2.1. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.4.4.9.3 RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.4.4.9.3.1. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET, BY APPLICATION
10.4.4.9.3.2. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET, BY APPLICATION
10.5. LATIN AMERICA
10.5.1 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.5.2 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.5.2.1 LATIN AMERICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.5.3 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.5.3.1 LATIN AMERICA RESEARCH APPLICATION MARKET, BY APPLICATION
10.5.3.2 LATIN AMERICA CLINICAL APPLICATION MARKET, BY APPLICATION
10.5.4 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY
10.5.4.1 BRAZIL
10.5.4.1.1 BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.5.4.1.2 BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.5.4.1.2.1. BRAZIL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.5.4.1.3 BRAZIL CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.5.4.1.3.1. BRAZIL RESEARCH APPLICATION MARKET, BY APPLICATION
10.5.4.1.3.2. BRAZIL CLINICAL APPLICATION MARKET, BY APPLICATION
10.5.4.2 MEXICO
10.5.4.2.1 MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.5.4.2.2 MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.5.4.2.2.1. MEXICO INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.5.4.2.3 MEXICO CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.5.4.2.3.1. MEXICO RESEARCH APPLICATION MARKET, BY APPLICATION
10.5.4.2.3.2. MEXICO CLINICAL APPLICATION MARKET, BY APPLICATION
10.5.4.3 REST OF LATAM
10.5.4.3.1 REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.5.4.3.2 REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.5.4.3.2.1. REST OF LATAM INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.5.4.3.3 REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.5.4.3.3.1. REST OF LATAM RESEARCH APPLICATION MARKET, BY APPLICATION
10.5.4.3.3.2. REST OF LATAM CLINICAL APPLICATION MARKET, BY APPLICATION
10.6. MIDDLE EAST
10.6.1 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.6.2 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.6.2.1 MIDDLE EAST INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.6.3 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.6.3.1 MIDDLE EAST RESEARCH APPLICATION MARKET, BY APPLICATION
10.6.3.2 MIDDLE EAST CLINICAL APPLICATION MARKET, BY APPLICATION
10.6.4 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY COUNTRY
10.6.4.1 ISREAL
10.6.4.1.1 ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.6.4.1.2 ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.6.4.1.2.1. ISREAL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.6.4.1.3 ISREAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.6.4.1.3.1. ISREAL RESEARCH APPLICATION MARKET, BY APPLICATION
10.6.4.1.3.2. ISREAL CLINICAL APPLICATION MARKET, BY APPLICATION
10.6.4.2 UAE
10.6.4.2.1 UAE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.6.4.2.2 UAE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.6.4.2.2.1. UAE INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.6.4.2.3 UAE CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.6.4.2.3.1. UAE RESEARCH APPLICATION MARKET, BY APPLICATION
10.6.4.2.3.2. UAE CLINICAL APPLICATION MARKET, BY APPLICATION
10.6.4.3 SAUDI ARABIA
10.6.4.3.1 SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.6.4.3.2 SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.6.4.3.2.1. SAUDI ARABIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.6.4.3.3 SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.6.4.3.3.1. SAUDI ARABIA RESEARCH APPLICATION MARKET, BY APPLICATION
10.6.4.3.3.2. SAUDI ARABIA CLINICAL APPLICATION MARKET, BY APPLICATION
10.6.4.4 REST OF THE MIDDLE EAST
10.6.4.4.1 REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.6.4.4.2 REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.6.4.4.2.1. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.6.4.4.3 REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.6.4.4.3.1. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET, BY APPLICATION
10.6.4.4.3.2. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET, BY APPLICATION
10.7. AFRICA
10.7.1 AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.7.2 AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.7.2.1 AFRICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.7.3 AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.7.3.1 AFRICA RESEARCH APPLICATION MARKET, BY APPLICATION
10.7.3.2 AFRICA CLINICAL APPLICATION MARKET, BY APPLICATION
10.7.4 AFRICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY
10.7.4.1 SOUTH AFRICA
10.7.4.1.1 SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.7.4.1.2 SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.7.4.1.2.1. SOUTH AFRICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.7.4.1.3 SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.7.4.1.3.1. SOUTH AFRICA RESEARCH APPLICATION MARKET, BY APPLICATION
10.7.4.1.3.2. SOUTH AFRICA CLINICAL APPLICATION MARKET, BY APPLICATION
10.7.4.2 NIGERIA
10.7.4.2.1 NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.7.4.2.2 NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.7.4.2.2.1. NIGERIA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.7.4.2.3 NIGERIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.7.4.2.3.1. NIGERIA RESEARCH APPLICATION MARKET, BY APPLICATION
10.7.4.2.3.2. NIGERIA CLINICAL APPLICATION MARKET, BY APPLICATION
10.7.4.3 REST OF AFRICA
10.7.4.3.1 REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
10.7.4.3.2 REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
10.7.4.3.2.1. REST OF AFRICA INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
10.7.4.3.3 REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
10.7.4.3.3.1. REST OF AFRICA RESEARCH APPLICATION MARKET, BY APPLICATION
10.7.4.3.3.2. REST OF AFRICA CLINICAL APPLICATION MARKET, BY APPLICATION
11. COMPANY PROFILES
11.1. LUCENCE HEALTH INC
11.1.1 COMPANY OVERVIEW
11.1.2 COMPANY SNAPSHOT
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY STRATEGIC MOVES & DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.2. F. HOFFMANN-LA ROCHE LTD
11.2.1 COMPANY OVERVIEW
11.2.2 COMPANY SNAPSHOT
11.2.3 OPERATING BUSINESS SEGMENTS
11.2.4 PRODUCT PORTFOLIO
11.2.5 BUSINESS PERFORMANCE
11.2.6 SALES BY BUSINESS SEGMENT
11.2.7 SALES BY GEOGRAPHIC SEGMENT
11.2.8 KEY STRATEGIC MOVES & DEVELOPMENTS
11.2.9 SWOT ANALYSIS
11.3. CARIS LIFE SCIENCES
11.3.1 COMPANY OVERVIEW
11.3.2 COMPANY SNAPSHOT
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY STRATEGIC MOVES & DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.4. ACT GENOMICS CO., LTD
11.4.1 COMPANY OVERVIEW
11.4.2 COMPANY SNAPSHOT
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY STRATEGIC MOVES & DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.5. THERMO FISHER SCIENTIFIC INC.
11.5.1 COMPANY OVERVIEW
11.5.2 COMPANY SNAPSHOT
11.5.3 OPERATING BUSINESS SEGMENTS
11.5.4 PRODUCT PORTFOLIO
11.5.5 BUSINESS PERFORMANCE
11.5.6 SALES BY BUSINESS SEGMENT
11.5.7 SALES BY GEOGRAPHIC SEGMENT
11.5.8 KEY STRATEGIC MOVES & DEVELOPMENTS
11.5.9 SWOT ANALYSIS
11.6. STRAND LIFE SCIENCES
11.6.1 COMPANY OVERVIEW
11.6.2 COMPANY SNAPSHOT
11.6.3 PRODUCT PORTFOLIO
11.6.4 SWOT ANALYSIS
11.7. IMB DX, INC.
11.7.1 COMPANY OVERVIEW
11.7.2 COMPANY SNAPSHOT
11.7.3 PRODUCT PORTFOLIO
11.7.4 SWOT ANALYSIS
11.8. ILLUMINA, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 COMPANY SNAPSHOT
11.8.3 PRODUCT PORTFOLIO
11.8.4 BUSINESS PERFORMANCE
11.8.5 SALES BY GEOGRAPHIC SEGMENT
11.8.6 KEY STRATEGIC MOVES & DEVELOPMENTS
11.8.7 SWOT ANALYSIS
11.9. GUARDANT HEALTH
11.9.1 COMPANY OVERVIEW
11.9.2 COMPANY SNAPSHOT
11.9.3 PRODUCT PORTFOLIO
11.9.4 BUSINESS PERFORMANCE
11.9.5 SALES BY GEOGRAPHIC SEGMENT
11.9.6 KEY STRATEGIC MOVES & DEVELOPMENTS
11.9.7 SWOT ANALYSIS
11.10. QIAGEN
11.10.1 COMPANY OVERVIEW
11.10.2 COMPANY SNAPSHOT
11.10.3 PRODUCT PORTFOLIO
11.10.4 BUSINESS PERFORMANCE
11.10.5 SALES BY GEOGRAPHIC SEGMENT
11.10.6 KEY STRATEGIC MOVES & DEVELOPMENTS
11.10.7 SWOT ANALYSIS
11.11. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.)
11.11.1 COMPANY OVERVIEW
11.11.2 COMPANY SNAPSHOT
11.11.3 PRODUCT PORTFOLIO
11.11.4 BUSINESS PERFORMANCE
11.11.5 SALES BY GEOGRAPHIC SEGMENT
11.11.6 KEY STRATEGIC MOVES & DEVELOPMENTS
11.11.7 SWOT ANALYSIS
11.12. NEOGENOMICS LABORATORIES
11.12.1 COMPANY OVERVIEW
11.12.2 COMPANY SNAPSHOT
11.12.3 OPERATING BUSINESS SEGMENTS
11.12.4 PRODUCT PORTFOLIO
11.12.5 BUSINESS PERFORMANCE
11.12.6 SALES BY BUSINESS SEGMENT
11.12.7 KEY STRATEGIC MOVES & DEVELOPMENTS
11.12.8 SWOT ANALYSIS
11.13. NANOSTRING
11.13.1 COMPANY OVERVIEW
11.13.2 COMPANY SNAPSHOT
11.13.3 PRODUCT PORTFOLIO
11.13.4 BUSINESS PERFORMANCE
11.13.5 SALES BY GEOGRAPHIC SEGMENT
11.13.6 KEY STRATEGIC MOVES & DEVELOPMENTS
11.13.7 SWOT ANALYSIS
11.14. HTG MOLECULAR DIAGNOSTICS, INC.
11.14.1 COMPANY OVERVIEW
11.14.2 COMPANY SNAPSHOT
11.14.3 PRODUCT PORTFOLIO
11.14.4 BUSINESS PERFORMANCE
11.14.5 SWOT ANALYSIS
11.15. RIBOMED BIOTECHNOLOGIES INC
11.15.1 COMPANY OVERVIEW
11.15.2 COMPANY SNAPSHOT
11.15.3 PRODUCT PORTFOLIO
11.15.4 SWOT ANALYSIS
LIST OF TABLES
TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 2. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 3. GENOMIC MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 4. GENOMIC MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 5. NORTH AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 6. NORTH AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 7. EUROPE GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 8. EUROPE GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 9. ASIA-PACIFIC GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 10. ASIA-PACIFIC GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 11. LATIN AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 12. LATIN AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 13. MIDDLE EAST GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 14. MIDDLE EAST GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 15. AFRICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 16. AFRICA GENOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 17. PROTEOMIC MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 18. PROTEOMIC MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 19. NORTH AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 20. NORTH AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 21. EUROPE PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 22. EUROPE PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 23. ASIA-PACIFIC PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 24. ASIA-PACIFIC PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 25. LATIN AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 26. LATIN AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 27. MIDDLE EAST PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 28. MIDDLE EAST PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 29. AFRICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 30. AFRICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 31. METABOLOMICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 32. METABOLOMICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 33. NORTH AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 34. NORTH AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 35. EUROPE METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 36. EUROPE METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 37. ASIA-PACIFIC METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 38. ASIA-PACIFIC METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 39. LATIN AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 40. LATIN AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 41. MIDDLE EAST METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 42. MIDDLE EAST METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 43. AFRICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 44. AFRICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 45. EPIGENETICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 46. EPIGENETICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 47. NORTH AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 48. NORTH AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 49. EUROPE EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 50. EUROPE EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 51. ASIA-PACIFIC EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 52. ASIA-PACIFIC EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 53. LATIN AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 54. LATIN AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 55. MIDDLE EAST EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 56. MIDDLE EAST EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 57. AFRICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 58. AFRICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 59. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 61. IMMUNOASSAY MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 62. IMMUNOASSAY MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 63. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 64. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 65. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 66. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 67. ASIA-PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 68. ASIA-PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 69. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 70. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 71. MIDDLE EAST IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 72. MIDDLE EAST IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 73. AFRICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 74. AFRICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 75. NGS MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 76. NGS MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 77. NORTH AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 78. NORTH AMERICA NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 79. EUROPE NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 80. EUROPE NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 81. ASIA-PACIFIC NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 82. ASIA-PACIFIC NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 83. LATIN AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 84. LATIN AMERICA NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 85. MIDDLE EAST NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 86. MIDDLE EAST NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 87. AFRICA NGS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 88. AFRICA NGS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 89. GLOBAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 90. GLOBAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 91. FISH MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 92. FISH MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 93. NORTH AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 94. NORTH AMERICA FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 95. EUROPE FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 96. EUROPE FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 97. ASIA-PACIFIC FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 98. ASIA-PACIFIC FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 99. LATIN AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 100. LATIN AMERICA FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 101. MIDDLE EAST FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 102. MIDDLE EAST FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 103. AFRICA FISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 104. AFRICA FISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 105. CISH MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 106. CISH MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 107. NORTH AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 108. NORTH AMERICA CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 109. EUROPE CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 110. EUROPE CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 111. ASIA-PACIFIC CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 112. ASIA-PACIFIC CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 113. LATIN AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 114. LATIN AMERICA CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 115. MIDDLE EAST CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 116. MIDDLE EAST CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 117. AFRICA CISH MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 118. AFRICA CISH MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 119. INSITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 120. INSITU HYBRIDIZATION MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 121. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 122. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 123. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 124. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 125. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 126. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 127. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 128. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 129. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 130. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 131. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 132. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 133. MASS SPECTROMETRY MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 134. MASS SPECTROMETRY MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 135. NORTH AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 136. NORTH AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 137. EUROPE MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 138. EUROPE MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 139. ASIA-PACIFIC MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 140. ASIA-PACIFIC MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 141. LATIN AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 142. LATIN AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 143. MIDDLE EAST MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 144. MIDDLE EAST MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 145. AFRICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 146. AFRICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 147. PCR MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 148. PCR MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 149. NORTH AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 150. NORTH AMERICA PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 151. EUROPE PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 152. EUROPE PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 153. ASIA-PACIFIC PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 154. ASIA-PACIFIC PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 155. LATIN AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 156. LATIN AMERICA PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 157. MIDDLE EAST PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 158. MIDDLE EAST PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 159. AFRICA PCR MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 160. AFRICA PCR MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 161. MICROARRAY MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 162. MICROARRAY MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 163. NORTH AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 164. NORTH AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 165. EUROPE MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 166. EUROPE MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 167. ASIA-PACIFIC MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 168. ASIA-PACIFIC MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 169. LATIN AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 170. LATIN AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 171. MIDDLE EAST MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 172. MIDDLE EAST MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 173. AFRICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 174. AFRICA MICROARRAY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 175. OTHERS MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 176. OTHERS MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 177. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 178. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 179. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 180. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 181. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 182. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 183. LATIN AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 184. LATIN AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 185. MIDDLE EAST OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 186. MIDDLE EAST OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 187. AFRICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 188. AFRICA OTHERS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 189. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 190. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 191. GLOBAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 192. GLOBAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 193. BIOMARKER DISCOVERY MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 194. BIOMARKER DISCOVERY MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 195. NORTH AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 196. NORTH AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 197. EUROPE BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 198. EUROPE BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 199. ASIA-PACIFIC BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 200. ASIA-PACIFIC BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 201. LATIN AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 202. LATIN AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 203. MIDDLE EAST BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 204. MIDDLE EAST BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 205. AFRICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 206. AFRICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 207. PERSONALIZED CANCER MEDICINE MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 208. PERSONALIZED CANCER MEDICINE MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 209. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 210. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 211. EUROPE PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 212. EUROPE PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 213. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 214. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 215. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 216. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 217. MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 218. MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 219. AFRICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 220. AFRICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 221. RESEARCH APPLICATION MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 222. RESEARCH APPLICATION MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 223. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 224. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 225. EUROPE RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 226. EUROPE RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 227. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 228. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 229. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 230. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 231. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 232. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 233. AFRICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 234. AFRICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 235. GLOBAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 236. GLOBAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 237. ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 238. ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 239. NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 240. NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 241. EUROPE ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 242. EUROPE ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 243. ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 244. ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 245. LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 246. LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 247. MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 248. MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 249. AFRICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 250. AFRICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 251. PROGNOSTICS MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 252. PROGNOSTICS MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 253. NORTH AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 254. NORTH AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 255. EUROPE PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 256. EUROPE PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 257. ASIA-PACIFIC PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 258. ASIA-PACIFIC PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 259. LATIN AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 260. LATIN AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 261. MIDDLE EAST PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 262. MIDDLE EAST PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 263. AFRICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 264. AFRICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 265. MONITORING AND TREATMENT MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 266. MONITORING AND TREATMENT MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 267. NORTH AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 268. NORTH AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 269. EUROPE MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 270. EUROPE MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 271. ASIA-PACIFIC MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 272. ASIA-PACIFIC MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 273. LATIN AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 274. LATIN AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 275. MIDDLE EAST MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 276. MIDDLE EAST MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 277. AFRICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 278. AFRICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 279. SCREENING MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 280. SCREENING MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 281. NORTH AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 282. NORTH AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 283. EUROPE SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 284. EUROPE SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 285. ASIA-PACIFIC SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 286. ASIA-PACIFIC SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 287. LATIN AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 288. LATIN AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 289. MIDDLE EAST SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 290. MIDDLE EAST SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 291. AFRICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 292. AFRICA SCREENING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 293. CLINICAL APPLICATION MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 294. CLINICAL APPLICATION MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 295. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 296. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 297. EUROPE CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 298. EUROPE CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 299. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 300. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 301. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 302. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 303. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 304. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 305. AFRICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 306. AFRICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 307. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY REGION, 2022-2025, MILLION USD
TABLE 308. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY REGION, 2026-2030, MILLION USD
TABLE 309. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 310. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 311. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 312. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 313. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 314. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 315. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 316. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 317. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 318. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 319. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 320. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 321. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 322. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 323. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 324. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 325. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 326. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 327. U.S. INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 328. U.S. INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 329. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 330. U.S. CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 331. U.S. RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 332. U.S. RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 333. U.S. CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 334. U.S. CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 335. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 336. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 337. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 338. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 339. CANADA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 340. CANADA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 341. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 342. CANADA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 343. CANADA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 344. CANADA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 345. CANADA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 346. CANADA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 347. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 348. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 349. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 350. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 351. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 352. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 353. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 354. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 355. EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 356. EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 357. EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 358. EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 359. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 360. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 361. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 362. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 363. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 364. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 365. GERMANY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 366. GERMANY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 367. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 368. GERMANY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 369. GERMANY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 370. GERMANY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 371. GERMANY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 372. GERMANY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 373. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 374. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 375. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 376. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 377. FRANCE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 378. FRANCE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 379. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 380. FRANCE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 381. FRANCE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 382. FRANCE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 383. FRANCE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 384. FRANCE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 385. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 386. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 387. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 388. UK CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 389. UK INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 390. UK INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 391. UK CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 392. UK CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 393. UK RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 394. UK RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 395. UK CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 396. UK CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 397. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 398. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 399. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 400. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 401. SPAIN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 402. SPAIN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 403. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 404. SPAIN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 405. SPAIN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 406. SPAIN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 407. SPAIN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 408. SPAIN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 409. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 410. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 411. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 412. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 413. ITALY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 414. ITALY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 415. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 416. ITALY CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 417. ITALY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 418. ITALY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 419. ITALY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 420. ITALY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 421. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 422. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 423. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 424. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 425. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 426. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 427. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 428. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 429. REST OF THE EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 430. REST OF THE EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 431. REST OF THE EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 432. REST OF THE EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 433. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 434. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 435. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 436. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 437. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 438. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 439. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 440. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 441. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 442. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 443. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 444. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 445. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 446. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 447. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 448. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 449. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 450. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 451. CHINA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 452. CHINA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 453. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 454. CHINA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 455. CHINA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 456. CHINA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 457. CHINA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 458. CHINA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 459. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 460. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 461. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 462. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 463. INDIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 464. INDIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 465. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 466. INDIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 467. INDIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 468. INDIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 469. INDIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 470. INDIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 471. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 472. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 473. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 474. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 475. JAPAN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 476. JAPAN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 477. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 478. JAPAN CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 479. JAPAN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 480. JAPAN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 481. JAPAN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 482. JAPAN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 483. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 484. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 485. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 486. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 487. SOUTH KOREA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 488. SOUTH KOREA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 489. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 490. SOUTH KOREA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 491. SOUTH KOREA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 492. SOUTH KOREA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 493. SOUTH KOREA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 494. SOUTH KOREA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 495. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 496. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 497. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 498. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 499. SINGAPORE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 500. SINGAPORE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 501. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 502. SINGAPORE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 503. SINGAPORE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 504. SINGAPORE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 505. SINGAPORE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 506. SINGAPORE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 507. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 508. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 509. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 510. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 511. AUSTRALIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 512. AUSTRALIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 513. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 514. AUSTRALIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 515. AUSTRALIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 516. AUSTRALIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 517. AUSTRALIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 518. AUSTRALIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 519. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 520. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 521. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 522. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 523. INDONESIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 524. INDONESIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 525. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 526. INDONESIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 527. INDONESIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 528. INDONESIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 529. INDONESIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 530. INDONESIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 531. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 532. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 533. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 534. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 535. VIETNAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 536. VIETNAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 537. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 538. VIETNAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 539. VIETNAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 540. VIETNAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 541. VIETNAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 542. VIETNAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 543. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 544. REST OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 545. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 546. REST OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 547. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 548. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 549. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 550. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 551. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 552. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 553. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 554. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 555. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 556. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 557. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 558. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 559. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 560. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 561. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 562. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 563. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 564. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 565. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 566. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 567. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 568. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 569. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 570. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 571. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 572. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 573. BRAZIL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 574. BRAZIL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 575. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 576. BRAZIL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 577. BRAZIL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 578. BRAZIL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 579. BRAZIL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 580. BRAZIL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 581. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 582. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 583. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 584. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 585. MEXICO INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 586. MEXICO INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 587. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 588. MEXICO CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 589. MEXICO RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 590. MEXICO RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 591. MEXICO CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 592. MEXICO CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 593. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 594. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 595. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 596. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 597. REST OF LATAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 598. REST OF LATAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 599. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 600. REST OF LATAM CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 601. REST OF LATAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 602. REST OF LATAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 603. REST OF LATAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 604. REST OF LATAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 605. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 606. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 607. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 608. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 609. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 610. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 611. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 612. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 613. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 614. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 615. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 616. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 617. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 618. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 619. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 620. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 621. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 622. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 623. ISREAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 624. ISREAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 625. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 626. ISREAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 627. ISREAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 628. ISREAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 629. ISREAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 630. ISREAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 631. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 632. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 633. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 634. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 635. UAE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 636. UAE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 637. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 638. UAE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 639. UAE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 640. UAE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 641. UAE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 642. UAE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 643. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 644. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 645. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 646. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 647. SAUDI ARABIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 648. SAUDI ARABIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 649. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 650. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 651. SAUDI ARABIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 652. SAUDI ARABIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 653. SAUDI ARABIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 654. SAUDI ARABIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 655. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 656. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 657. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 658. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 659. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 660. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 661. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 662. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 663. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 664. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 665. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 666. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 667. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 668. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 669. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 670. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 671. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 672. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 673. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 674. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 675. AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 676. AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 677. AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 678. AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 679. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2025, MILLION USD
TABLE 680. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2026-2030, MILLION USD
TABLE 681. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 682. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 683. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 684. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 685. SOUTH AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 686. SOUTH AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 687. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 688. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 689. SOUTH AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 690. SOUTH AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 691. SOUTH AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 692. SOUTH AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 693. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 694. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 695. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 696. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 697. NIGERIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 698. NIGERIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 699. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 700. NIGERIA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 701. NIGERIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 702. NIGERIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 703. NIGERIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 704. NIGERIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 705. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2025, MILLION USD
TABLE 706. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2026-2030, MILLION USD
TABLE 707. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 708. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 709. REST OF AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2025, MILLION USD
TABLE 710. REST OF AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2026-2030, MILLION USD
TABLE 711. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 712. REST OF AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 713. REST OF AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 714. REST OF AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 715. REST OF AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2025, MILLION USD
TABLE 716. REST OF AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2026-2030, MILLION USD
TABLE 717. LUCENCE HEALTH INC: COMPANY SNAPSHOT
TABLE 718. LUCENCE HEALTH INC: PRODUCT PORTFOLIO
TABLE 719. LUCENCE HEALTH INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 720. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 721. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 722. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 723. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 724. CARIS LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 725. CARIS LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 726. CARIS LIFE SCIENCES: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 727. ACT GENOMICS CO., LTD: COMPANY SNAPSHOT
TABLE 728. ACT GENOMICS CO., LTD: PRODUCT PORTFOLIO
TABLE 729. ACT GENOMICS CO., LTD: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 730. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 731. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
TABLE 732. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 733. THERMO FISHER SCIENTIFIC INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 734. STRAND LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 735. STRAND LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 736. IMB DX, INC.: COMPANY SNAPSHOT
TABLE 737. IMB DX, INC.: PRODUCT PORTFOLIO
TABLE 738. ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 739. ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 740. ILLUMINA, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 741. GUARDANT HEALTH: COMPANY SNAPSHOT
TABLE 742. GUARDANT HEALTH: PRODUCT PORTFOLIO
TABLE 743. GUARDANT HEALTH: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 744. QIAGEN: COMPANY SNAPSHOT
TABLE 745. QIAGEN: PRODUCT PORTFOLIO
TABLE 746. QIAGEN: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 747. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): COMPANY SNAPSHOT
TABLE 748. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): PRODUCT PORTFOLIO
TABLE 749. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 750. NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT
TABLE 751. NEOGENOMICS LABORATORIES: OPERATING SEGMENTS
TABLE 752. NEOGENOMICS LABORATORIES: PRODUCT PORTFOLIO
TABLE 753. NEOGENOMICS LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 754. NANOSTRING: COMPANY SNAPSHOT
TABLE 755. NANOSTRING: PRODUCT PORTFOLIO
TABLE 756. NANOSTRING: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 757. HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT
TABLE 758. HTG MOLECULAR DIAGNOSTICS, INC.: PRODUCT PORTFOLIO
TABLE 759. RIBOMED BIOTECHNOLOGIES INC: COMPANY SNAPSHOT
TABLE 760. RIBOMED BIOTECHNOLOGIES INC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. MARKET SHARE ANALYSIS OF TOP GLOBAL CANCER/TUMOR PROFILING PROVIDERS, 2022
FIGURE 2. MARKET SHARE ANALYSIS OF TOP NORTH AMERICA CANCER/TUMOR PROFILING PROVIDERS, 2022
FIGURE 3. MARKET SHARE ANALYSIS OF TOP EUROPE CANCER/TUMOR PROFILING PROVIDERS, 2022
FIGURE 4. MARKET SHARE ANALYSIS OF TOP APAC CANCER/TUMOR PROFILING PROVIDERS, 2022
FIGURE 5. MARKET SHARE ANALYSIS OF TOP ROW CANCER/TUMOR PROFILING PROVIDERS, 2022
FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 7. GENOMIC MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 8. NORTH AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 9. EUROPE GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 10. ASIA-PACIFIC GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 11. LATIN AMERICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 12. MIDDLE EAST GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 13. AFRICA GENOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 14. PROTEOMIC MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 15. NORTH AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 16. EUROPE PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 17. ASIA-PACIFIC PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 18. LATIN AMERICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 19. MIDDLE EAST PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 20. AFRICA PROTEOMIC MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 21. METABOLOMICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 22. NORTH AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 23. EUROPE METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 24. ASIA-PACIFIC METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 25. LATIN AMERICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 26. MIDDLE EAST METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 27. AFRICA METABOLOMICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 28. EPIGENETICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 29. NORTH AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 30. EUROPE EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 31. ASIA-PACIFIC EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 32. LATIN AMERICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 33. MIDDLE EAST EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 34. AFRICA EPIGENETICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 35. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 36. IMMUNOASSAY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 37. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 38. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 39. ASIA-PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 40. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 41. MIDDLE EAST IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 42. AFRICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 43. NGS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 44. NORTH AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 45. EUROPE NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 46. ASIA-PACIFIC NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 47. LATIN AMERICA NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 48. MIDDLE EAST NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 49. AFRICA NGS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 50. GLOBAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 51. FISH MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 52. NORTH AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 53. EUROPE FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 54. ASIA-PACIFIC FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 55. LATIN AMERICA FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 56. MIDDLE EAST FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 57. AFRICA FISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 58. CISH MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 59. NORTH AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 60. EUROPE CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 61. ASIA-PACIFIC CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 62. LATIN AMERICA CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 63. MIDDLE EAST CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 64. AFRICA CISH MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 65. INSITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 66. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 67. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 68. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 69. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 70. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 71. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 72. MASS SPECTROMETRY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 73. NORTH AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 74. EUROPE MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 75. ASIA-PACIFIC MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 76. LATIN AMERICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 77. MIDDLE EAST MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 78. AFRICA MASS SPECTROMETRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 79. PCR MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 80. NORTH AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 81. EUROPE PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 82. ASIA-PACIFIC PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 83. LATIN AMERICA PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 84. MIDDLE EAST PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 85. AFRICA PCR MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 86. MICROARRAY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 87. NORTH AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 88. EUROPE MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 89. ASIA-PACIFIC MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 90. LATIN AMERICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 91. MIDDLE EAST MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 92. AFRICA MICROARRAY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 93. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 94. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 95. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 96. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 97. LATIN AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 98. MIDDLE EAST OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 99. AFRICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 100. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 101. GLOBAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 102. BIOMARKER DISCOVERY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 103. NORTH AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 104. EUROPE BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 105. ASIA-PACIFIC BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 106. LATIN AMERICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 107. MIDDLE EAST BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 108. AFRICA BIOMARKER DISCOVERY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 109. PERSONALIZED CANCER MEDICINE MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 110. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 111. EUROPE PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 112. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 113. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 114. MIDDLE EAST PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 115. AFRICA PERSONALIZED CANCER MEDICINE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 116. RESEARCH APPLICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 117. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 118. EUROPE RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 119. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 120. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 121. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 122. AFRICA RESEARCH APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 123. GLOBAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 124. ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 125. NORTH AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 126. EUROPE ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 127. ASIA-PACIFIC ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 128. LATIN AMERICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 129. MIDDLE EAST ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 130. AFRICA ONCOLOGICAL DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 131. PROGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 132. NORTH AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 133. EUROPE PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 134. ASIA-PACIFIC PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 135. LATIN AMERICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 136. MIDDLE EAST PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 137. AFRICA PROGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 138. MONITORING AND TREATMENT MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 139. NORTH AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 140. EUROPE MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 141. ASIA-PACIFIC MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 142. LATIN AMERICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 143. MIDDLE EAST MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 144. AFRICA MONITORING AND TREATMENT MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 145. SCREENING MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 146. NORTH AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 147. EUROPE SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 148. ASIA-PACIFIC SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 149. LATIN AMERICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 150. MIDDLE EAST SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 151. AFRICA SCREENING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 152. CLINICAL APPLICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 153. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 154. EUROPE CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 155. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 156. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 157. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 158. AFRICA CLINICAL APPLICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 159. GLOBAL CANCER/TUMOR PROFILING MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 160. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 161. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 162. NORTH AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 163. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 164. NORTH AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 165. NORTH AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 166. NORTH AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 167. U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 168. U.S. CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 169. U.S. INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 170. U.S. CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 171. U.S. RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 172. U.S. CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 173. CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 174. CANADA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 175. CANADA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 176. CANADA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 177. CANADA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 178. CANADA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 179. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 180. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 181. EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 182. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 183. EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 184. EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 185. EUROPE CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 186. GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 187. GERMANY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 188. GERMANY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 189. GERMANY CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 190. GERMANY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 191. GERMANY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 192. FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 193. FRANCE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 194. FRANCE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 195. FRANCE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 196. FRANCE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 197. FRANCE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 198. UK CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 199. UK CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 200. UK INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 201. UK CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 202. UK RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 203. UK CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 204. SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 205. SPAIN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 206. SPAIN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 207. SPAIN CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 208. SPAIN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 209. SPAIN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 210. ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 211. ITALY CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 212. ITALY INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 213. ITALY CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 214. ITALY RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 215. ITALY CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 216. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 217. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 218. REST OF THE EUROPE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 219. REST OF THE EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 220. REST OF THE EUROPE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 221. REST OF THE EUROPE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 222. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 223. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 224. ASIA-PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 225. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 226. ASIA-PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 227. ASIA-PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 228. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 229. CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 230. CHINA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 231. CHINA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 232. CHINA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 233. CHINA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 234. CHINA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 235. INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 236. INDIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 237. INDIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 238. INDIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 239. INDIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 240. INDIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 241. JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 242. JAPAN CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 243. JAPAN INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 244. JAPAN CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 245. JAPAN RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 246. JAPAN CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 247. SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 248. SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 249. SOUTH KOREA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 250. SOUTH KOREA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 251. SOUTH KOREA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 252. SOUTH KOREA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 253. SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 254. SINGAPORE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 255. SINGAPORE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 256. SINGAPORE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 257. SINGAPORE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 258. SINGAPORE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 259. AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 260. AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 261. AUSTRALIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 262. AUSTRALIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 263. AUSTRALIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 264. AUSTRALIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 265. INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 266. INDONESIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 267. INDONESIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 268. INDONESIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 269. INDONESIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 270. INDONESIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 271. VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 272. VIETNAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 273. VIETNAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 274. VIETNAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 275. VIETNAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 276. VIETNAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 277. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 278. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 279. RES OF THE ASIA PACIFIC INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 280. RES OF THE ASIA PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 281. RES OF THE ASIA PACIFIC RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 282. RES OF THE ASIA PACIFIC CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 283. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 284. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 285. LATIN AMERICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 286. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 287. LATIN AMERICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 288. LATIN AMERICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 289. LATIN AMERICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 290. BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 291. BRAZIL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 292. BRAZIL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 293. BRAZIL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 294. BRAZIL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 295. BRAZIL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 296. MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 297. MEXICO CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 298. MEXICO INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 299. MEXICO CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 300. MEXICO RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 301. MEXICO CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 302. REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 303. REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 304. REST OF LATAM INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 305. REST OF LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 306. REST OF LATAM RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 307. REST OF LATAM CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 308. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 309. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 310. MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 311. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 312. MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 313. MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 314. MIDDLE EAST CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 315. ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 316. ISREAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 317. ISREAL INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 318. ISREAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 319. ISREAL RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 320. ISREAL CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 321. UAE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 322. UAE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 323. UAE INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 324. UAE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 325. UAE RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 326. UAE CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 327. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 328. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 329. SAUDI ARABIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 330. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 331. SAUDI ARABIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 332. SAUDI ARABIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 333. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 334. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 335. REST OF THE MIDDLE EAST INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 336. REST OF THE MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 337. REST OF THE MIDDLE EAST RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 338. REST OF THE MIDDLE EAST CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 339. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 340. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 341. AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 342. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 343. AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 344. AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 345. AFRICA CANCER/TUMOR PROFILING MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 346. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 347. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 348. SOUTH AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 349. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 350. SOUTH AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 351. SOUTH AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 352. NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 353. NIGERIA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 354. NIGERIA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 355. NIGERIA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 356. NIGERIA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 357. NIGERIA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 358. REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 359. REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 360. REST OF AFRICA INSITU HYBRIDIZATION MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 361. REST OF AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 362. REST OF AFRICA RESEARCH APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 363. REST OF AFRICA CLINICAL APPLICATION MARKET VALUE, BY APPLICATION, 2022-2030, MILLION USD
FIGURE 364. LUCENCE HEALTH INC: SWOT ANALYSIS
FIGURE 365. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2018–2022 ($MILLION)
FIGURE 366. F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 367. CARIS LIFE SCIENCES.: SWOT ANALYSIS
FIGURE 368. ACT GENOMICS CO., LTD.: SWOT ANALYSIS
FIGURE 369. THERMO FISHER SCIENTIFIC INC: NET SALES, 2018–2022 ($MILLION)
FIGURE 370. THERMO FISHER SCIENTIFIC INC: SWOT ANALYSIS
FIGURE 371. STRAND LIFE SCIENCES: SWOT ANALYSIS
FIGURE 372. IMB DX, INC.: SWOT ANALYSIS
FIGURE 373. ILLUMINA, INC.: NET SALES, 2018–2022 ($MILLION)
FIGURE 374. ILLUMINA, INC: SWOT ANALYSIS
FIGURE 375. GUARDANT HEALTH: NET SALES, 2018–2022 ($MILLION)
FIGURE 376. GUARDANT HEALTH: SWOT ANALYSIS
FIGURE 377. QIAGEN: NET SALES, 2018–2022 ($MILLION)
FIGURE 378. QIAGEN: SWOT ANALYSIS
FIGURE 379. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): NET SALES, 2018–2022 ($MILLION)
FIGURE 380. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.): SWOT ANALYSIS
FIGURE 381. NEOGENOMICS LABORATORIES: NET SALES, 2018–2022 ($MILLION)
FIGURE 382. NEOGENOMICS LABORATORIES: SWOT ANALYSIS
FIGURE 383. NANOSTRING: NET SALES, 2018–2022 ($MILLION)
FIGURE 384. NANOSTRING: SWOT ANALYSIS
FIGURE 385. HTG MOLECULAR DIAGNOSTICS, INC.: NET SALES, 2018–2022 ($MILLION)
FIGURE 386. HTG MOLECULAR DIAGNOSTICS, INC.: SWOT ANALYSIS
FIGURE 387. RIBOMED BIOTECHNOLOGIES INC: SWOT ANALYSIS